AU2003249693A8 - Peptides presented by hla-b18 and cw16 molecules, and uses thereof - Google Patents

Peptides presented by hla-b18 and cw16 molecules, and uses thereof

Info

Publication number
AU2003249693A8
AU2003249693A8 AU2003249693A AU2003249693A AU2003249693A8 AU 2003249693 A8 AU2003249693 A8 AU 2003249693A8 AU 2003249693 A AU2003249693 A AU 2003249693A AU 2003249693 A AU2003249693 A AU 2003249693A AU 2003249693 A8 AU2003249693 A8 AU 2003249693A8
Authority
AU
Australia
Prior art keywords
hla
molecules
peptides presented
peptides
presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003249693A
Other versions
AU2003249693A1 (en
Inventor
Catia Traversari
Christophe Panichelli
Pierre Van Der Bruggen
Yi Zhang
Thierry Boon-Falleur
Janine Bilsborough
Erwin Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/164,078 external-priority patent/US7041502B2/en
Priority claimed from US10/164,121 external-priority patent/US20030228308A1/en
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU2003249693A1 publication Critical patent/AU2003249693A1/en
Publication of AU2003249693A8 publication Critical patent/AU2003249693A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AU2003249693A 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF Abandoned AU2003249693A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/164,121 2002-06-05
US10/164,078 US7041502B2 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-B18 molecules and uses thereof
US10/164,121 US20030228308A1 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
US10/164,078 2002-06-05
PCT/US2003/017641 WO2003104259A2 (en) 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2003249693A1 AU2003249693A1 (en) 2003-12-22
AU2003249693A8 true AU2003249693A8 (en) 2003-12-22

Family

ID=29738933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003249693A Abandoned AU2003249693A1 (en) 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Country Status (2)

Country Link
AU (1) AU2003249693A1 (en)
WO (1) WO2003104259A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702517B2 (en) * 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7041502B2 (en) * 2002-06-05 2006-05-09 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B18 molecules and uses thereof

Also Published As

Publication number Publication date
AU2003249693A1 (en) 2003-12-22
WO2003104259A3 (en) 2004-07-08
WO2003104259A2 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
EP1617807A4 (en) Substituted 1,4-diazepines and uses thereof
EP1575534A4 (en) D4,5 glycuronidase and uses thereof
IL172653A0 (en) Novel ??-actin and rps21 promoters and uses thereof
AU2003207940A1 (en) Conformationally constrained c-backbone cyclic peptides
AU2003290563A8 (en) Leptin-related peptides
EP1578787A4 (en) Novel chi-conotoxin peptides (-ii)
WO2004092197A8 (en) Amyloid-specific peptides and uses thereof
IL156263A0 (en) Livin-derived peptides, compositions and uses thereof
EP1572168A3 (en) Anti-infarction molecules
GB0324457D0 (en) Modified peptides and their uses
AU2003249693A8 (en) Peptides presented by hla-b18 and cw16 molecules, and uses thereof
EP1487547A4 (en) Physical interaction means and related uses thereof
EP1660088A4 (en) Pyridomorphinans, pyridazinomorphinans and use thereof
AU2003219732A8 (en) Oligomeric molecules and uses thereof
EP1699809A4 (en) Amniotic-derived peptide and uses thereof
GB0219980D0 (en) Peptides
AUPS161602A0 (en) Novel molecules and uses therefor
GB0312992D0 (en) Peptides,compositions and uses thereof
GB0211232D0 (en) Molecules
GB0209619D0 (en) Molecules
GB0323193D0 (en) Peptides and uses thereof
GB0312990D0 (en) Peptides and uses thereof
AU2003239717A8 (en) Card-4 molecules and uses thereof
AU2003220067A8 (en) Jade nucleic acids, proteins and uses thereof
AU2003231478A1 (en) Novel protein, its dna and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase